Preface

As of the end of 2021, over 290 million people have been infected with SARS-CoV-2 worldwide. The ongoing global COVID-19 pandemic has caused unprecedented disruption of our lives. In 2022, we will still face many pandemic uncertainties and challenges. However, on a positive note, in the past year, we have witnessed the rapid development and deployment of COVID-19 vaccines and anti-viral drugs. These great scientific achievements are direct results of many years of basic research in biomedicine and biosciences, including basic research in understanding viruses. I am confident that with the new pandemic-fighting tools, the current COVID19 pandemic will end in the near future. For the HIV/AIDS pandemic, we will continue to look for an effective vaccine to control HIV transmission. We are also looking for a cure or functional cure to end the 40 year-long pandemic. The goal of Current HIV Research is aligned with the ongoing scientific quests for an HIV vaccine and cure. Our journal will continue to focus on disseminating new knowledge in basic HIV research and clinical management of chronic HIV disease. In addition, we have recently expanded the scope of our journal to include research in immune diseases caused by HIV and other viruses. We publish manuscripts addressing global issues of HIV/AIDS, and virus-induced immune diseases, such as immune deficiency, immune dysfunction, and autoimmune diseases.

This year is the 20th year since the first publication of Current HIV Research. For 2022 and beyond, Current HIV Research will continue to serve as an important forum to publish advances in HIV/AIDS research and virus-induced immune diseases. Our journal has a great editorial board, with many distinguished world-class leaders in the HIV/AIDS, virology, and immunology fields. We will continue to work together to improve the journal for higher quality, faster publication, and better open access. We will also put more emphasis on publishing thematic issues to highlight new advances in HIV/AIDS research and virus-induced immune diseases.

I would like to take this opportunity to thank all the authors and readers for their continuous support. I would also like to thank our reviewers, editors, and editorial board members for their efforts, and our supporting editorial staff for their dedication and support.

Yuntao Wu, Ph.D
( Editor-in-Chief)
Professor
Center for Infectious Disease Research
School of Systems Biology
George Mason University
Manassas, VA 20110
Tel: 703 993 4299
Email: ywu8@gmu.edu